Answers are grounded in this paper and cite their sources.
Compared with PD-L1, HHLA2 is more prevalent and possesses more explicit prognostic significance, which confer the rationale for HHLA2 as a potential immunotherapeutic target next to PD-L1 for ICC patients.
No takes yet. Share an insight, caveat, or question.
Jing et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: